Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 ye...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2021-10, Vol.56 (10), p.2367-2381
Hauptverfasser: Hayden, Patrick J., Eikema, Dirk-Jan, de Wreede, Liesbeth C., Koster, Linda, Kröger, Nicolaus, Einsele, Hermann, Minnema, Monique, Dominietto, Alida, Potter, Michael, Passweg, Jacob, Bermúdez, Arancha, Nguyen-quoc, Stephanie, Platzbecker, Uwe, Tischer, Johanna, Ciceri, Fabio, Veelken, Joan Hendrik, Ljungman, Per, Schaap, Nicolaas, Forcade, Edouard, Carella, Angelo Michele, Gandemer, Virginie, Arcese, William, Bloor, Adrian, Olivieri, Attilio, Vincent, Laure, Beksac, Meral, Schönland, Stefan, Yakoub-Agha, Ibrahim
Format: Artikel
Sprache:eng
Schlagworte:
692/700/565/2319
692/700/565/251
Allografts
Cancer
Care and treatment
Cell Biology
Graft rejection
Graft vs Host Disease
Graft-versus-host reaction
Grafts
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Histocompatibility antigen HLA
Humans
Internal Medicine
Life Sciences
Medicin och hälsovetenskap
Medicine
Medicine & Public Health
Multiple myeloma
Multiple Myeloma - therapy
Multivariate analysis
Neoplasm Recurrence, Local
Patient outcomes
Public Health
Relapse
Retrospective Studies
Stem cell transplantation
Stem Cells
Transplantation
Transplantation Conditioning
Transplants
Transplants & implants
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24–46%); Others 9% (0–17%), p  
ISSN:0268-3369
1476-5365
1476-5365
DOI:10.1038/s41409-021-01286-x